Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation

Orally-active senolytics can boost a key beneficial protein in mice and humans

Orally-active senolytics can boost a key beneficial protein in mice and humans

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Study shows positive outcomes in COVID-19 patients who underwent lung transplants

Study shows positive outcomes in COVID-19 patients who underwent lung transplants

Scientists discover new insights about lymphangioleiomyomatosis

Scientists discover new insights about lymphangioleiomyomatosis

Composition of microbes in the lower airways is different for patients with idiopathic pulmonary fibrosis

Composition of microbes in the lower airways is different for patients with idiopathic pulmonary fibrosis

Role of leptin in immune modulation and pathophysiology of COVID-19

Role of leptin in immune modulation and pathophysiology of COVID-19

Correlation between idiopathic pulmonary fibrosis and COVID-19

Correlation between idiopathic pulmonary fibrosis and COVID-19

3D cell culturing platform allows study of idiopathic pulmonary fibrosis

3D cell culturing platform allows study of idiopathic pulmonary fibrosis

Updated mapping of the human genetic architecture of COVID-19

Updated mapping of the human genetic architecture of COVID-19

A possible protective genetic polymorphism in COVID-19

A possible protective genetic polymorphism in COVID-19

Repeated injury to the epithelial tissue of airways causes "biological aging" of stem cells

Repeated injury to the epithelial tissue of airways causes "biological aging" of stem cells

Researchers receive $12.8M renewal grant to reveal how smoking causes distinct lung diseases

Researchers receive $12.8M renewal grant to reveal how smoking causes distinct lung diseases

New model shows how dysfunction in the air sacs initiates fibrotic cascade

New model shows how dysfunction in the air sacs initiates fibrotic cascade

Study suggests a novel therapeutic target to reverse lung fibrosis

Study suggests a novel therapeutic target to reverse lung fibrosis

Single-cell RNA sequencing reveals cells that could protect from fatal lung disease

Single-cell RNA sequencing reveals cells that could protect from fatal lung disease